Alzheimers disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1)Patients meeting the 2023 NIA-AA clinical diagnostic criteria for Alzheimer's disease (AD) with Stage 3-4 manifestations; 2)Aged 50-85 years; 3)Right-handed; 4)Clinically stable condition; if using cognitive enhancers (e.g. Donepezil Hydrochloride or Memantine Hydrochloride) a stable dosage must have been maintained for at least 3 months.
Exclusion criteria
Exclusion criteria: 1)Individuals with visual or auditory impairments that preclude cooperation in completing assessments; 2)Presence of metal implants (e.g. stents pacemakers cochlear implants); 3)History of severe traumatic brain injury stroke migraine epilepsy familial psychiatric disorders or other neurological diseases affecting cognitive function; 4)Severe primary diseases involving the cardiovascular hepatic renal hematopoietic or endocrine systems; infectious/contagious diseases; bleeding tendency or hemorrhagic disorders; life-threatening conditions; or life expectancy <1 year; 5)History of fainting during needle procedures or at the sight of blood; 6)Substance abuse or addictive behaviors; 7)Current participation in other clinical trials or refusal to sign informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ADAS-cognitive subscale (ADAS-Cog); | — |
Secondary
| Measure | Time frame |
|---|---|
| amyloid beta related blood samples;Mini-mental State Examination(MMSE);Neuropsychiatric Inventory (NPI); | — |
Countries
China
Contacts
The Affiliated TCM Hospital of Guangzhou Medical University